Bristol-Myers
Squibb Company (NYSE:BMY) today announced that they have entered
into a collaboration agreement with The Sidney Kimmel Comprehensive
Cancer Center at Johns Hopkins as part of Bristol-Myers Squibb’s
Immuno-Oncology Rare Population Malignancy (I-O RPM) program in the U.S.
The I-O RPM research program is a multi-institutional initiative with
academic-based cancer centers focused on the clinical investigation of
immuno-oncology therapeutics as potential treatment options for patients
with high risk, poor prognostic cancers, defined as a rare population
malignancy.
As part of the I-O RPM program, Bristol-Myers Squibb and the Johns
Hopkins Kimmel Cancer Center will conduct a range of early phase
clinical studies and Bristol-Myers Squibb will fund positions within The
Johns Hopkins University School of Medicine fellowship program.
“Johns Hopkins has been a long-time collaborator with Bristol-Myers
Squibb in immuno-oncology research,” said Laura Bessen, M.D., head of
U.S. Medical, Bristol-Myers Squibb. “We look forward to working with
them as part of the I-O RPM research program as we continue to advance
the science in this innovative field of cancer research and development,
particularly among subpopulations of patients with high risk, poor
prognostic cancers.”
About I-O RPM
Immuno-oncology is an innovative approach to cancer research and
treatment that is designed to harness the body’s own immune system to
fight cancer. The I-O RPM research program focuses on significant areas
of high unmet need marked by poor outcomes among patients with rare
population malignancies. A rare population malignancy is a subpopulation
within a higher incident disease population. These patients have
aggressive disease with an increased potential for early metastasis to
multiple sites and/or are initially refractory or subject to early
recurrences with conventional cancer therapies. Existing clinical
research provide a strong rationale for further research into the
potential of immunotherapies for these cancers.
The I-O RPM research program is a multi-institutional initiative with
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
and the Northwestern Medicine Developmental Therapeutics Institute,
Moffitt Cancer Center and now the Johns Hopkins Kimmel Cancer Center.
I-O RPM builds on Bristol-Myers Squibb’s formation in 2012 of the
International Immuno-Oncology Network (II-ON), which is a global
collaboration between Bristol-Myers Squibb and academia focused on
facilitating the translation of scientific research findings into
clinical trials and, eventually, clinical practice.
About Bristol Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose mission
is to discover, develop and deliver innovative medicines that help
patients prevail over serious diseases. For more information, please
visit www.bms.com
or follow us on Twitter at http://twitter.com/bmsnews.
Bristol-Myers Squibb Forward-Looking Statement
This press release contains “forward-looking statements” as that term
is defined in the Private Securities Litigation Reform Act of 1995
regarding the research, development and commercialization of
pharmaceutical products. Such forward-looking statements are based on
current expectations and involve inherent risks and uncertainties,
including factors that could delay, divert or change any of them, and
could cause actual outcomes and results to differ materially from
current expectations. No forward-looking statement can be guaranteed.
Among other risks, there can be no guarantee that the immunotherapies
discussed in this release will be successfully developed or approved for
any of the indications described in this release. Forward-looking
statements in this press release should be evaluated together with the
many uncertainties that affect Bristol-Myers Squibb's business,
particularly those identified in the cautionary factors discussion in
Bristol-Myers Squibb's Annual Report on Form 10-K for the year ended
December 31, 2014 in our Quarterly Reports on Form 10-Q and our Current
Reports on Form 8-K. Bristol-Myers Squibb undertakes no obligation to
publicly update any forward-looking statement, whether as a result of
new information, future events or otherwise.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151103006304/en/
Copyright Business Wire 2015